Cross-Lagged Trajectory Model · 7-Layer Decision Algorithm
eGFR < 60 mL/min
Bicarb 12–21 mEq/L
Not on chronic dialysis
1
Patient Demographics
2
Medications & Flags
Diabetes mellitus
Blunts ammoniagenesis → longer lag
Current alkali therapy
NaHCO₃ or Na-citrate supplement
ACEi / ARB (RAASi)
Minor eGFR-stabilizing effect
Currently on chronic dialysis
Hard exclusion (HD or PD)
Prior kidney transplant
Eligible — note for clinical review
Hospitalization in past 8 weeks
May distort bicarb trajectory
3
Serial Lab Values
Date
eGFR
Bicarb
No readings yet
ℹ Minimum 2 sets of labs required to generate a trajectory. More readings improve prediction accuracy — at least 3 labs spanning ≥ 2 months is preferred.
4
Screening Parameters
🔬
Ready to Predict
Enter patient demographics, medications, and serial lab values on the left,
then click Run Eligibility Prediction to see the traffic light output.
Click Load Example to see the index case (bicarb 22–23 at screening).
⬜
—
—
Predicted Bicarb
—
95% CI: —
Qualify Probability
—
P(bicarb 12–21)
Projected eGFR
—
at screening
Days to Screen
—
—
Trajectory — eGFR & Bicarbonate Over Time
eGFRobserved
Bicarbobserved
Bicarbpredicted ± CI
Algorithm Layer Breakdown
🩸 Venous Blood Gas Predictor
Estimated VBG parameters assuming chronic metabolic acidosis with appropriate respiratory compensation.
Ranges incorporate Winter's formula ± physiological wiggle room for mild over/undercompensation and chronic respiratory conditions. Not valid for acute acid-base disturbances.
Venous pH
—
range: —
Venous pCO₂ (mmHg)
—
range: —
Respiratory Compensation Adequacy
Undercompensated—Overcompensated
—
⚠️
Research Use & Pre-Screening Tool Only — Not for Clinical or Diagnostic Use
This tool is intended solely for use by qualified research personnel to assist in assessing potential
screening eligibility for the REVIVE Study, a clinical trial sponsored by
Renibus Therapeutics. It is designed as a pre-screening aid only and does
not constitute medical advice, clinical diagnosis, or a basis for clinical
decision-making of any kind. All outputs are predictive estimates based on a statistical model
that has not been prospectively validated and may not reflect individual patient circumstances.
Final eligibility determinations must be made by a qualified investigator in accordance with the
official REVIVE Study protocol, applicable regulatory requirements, and independent clinical
judgment. This tool does not establish a patient–provider relationship and must not be used as
a substitute for professional medical evaluation. Renibus Therapeutics and its affiliates make
no warranties, express or implied, regarding the accuracy, completeness, or fitness for any
particular purpose of this tool or its outputs.
